SB12 (Proposed Eculizumab Biosimilar)

eculizumab biosimilar · Samsung Bioepis Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SB12 (Proposed Eculizumab Biosimilar), covering 2024-03-26 to 2024-03-26. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria [Phase 3]

See pricing